[HTML][HTML] Evaluation of the procoagulant state in chronic immune thrombocytopenia before and after eltrombopag treatment—a prospective cohort study
WEM van Dijk, GC Poolen, A Huisman… - Journal of Thrombosis …, 2023 - Elsevier
Background Thrombopoietin receptor agonists are frequently used in treating immune
thrombocytopenia (ITP) owing to high response rates and good tolerability. ITP is associated
with an increased risk of thrombosis. Whether treatment with eltrombopag further increases
this risk is controversial. The mechanisms behind the thrombotic risk in ITP are unclear.
Objectives To assess platelet function and hypercoagulability in patients with ITP and the
effect of eltrombopag thereon. Methods This prospective multicenter study assessed adult …
thrombocytopenia (ITP) owing to high response rates and good tolerability. ITP is associated
with an increased risk of thrombosis. Whether treatment with eltrombopag further increases
this risk is controversial. The mechanisms behind the thrombotic risk in ITP are unclear.
Objectives To assess platelet function and hypercoagulability in patients with ITP and the
effect of eltrombopag thereon. Methods This prospective multicenter study assessed adult …
以上显示的是最相近的搜索结果。 查看全部搜索结果